Our Myolex® mission is to gain FDA-approval to assess, monitor, and display changes in skeletal muscle composition and structure to aid in the diagnosis, prognosis, and treatment of neuromuscular conditions. We are deeply committed to helping the dedicated clinicians, scientists, caregivers, and above all, patients who are battling these diseases every day, especially those who have a life-threating or irreversibly debilitating human disease, such as amyotrophic lateral sclerosis (ALS) and Duchenne muscular dystrophy (DMD). Our patented electrical impedance myography (EIM) technology was originally developed by Myolex founder Dr. Seward Rutkove, the Nancy Lurie Marks Chair of the Department of Neurology at Beth Israel Deaconess Medical Center, and Professor of Neurology at Harvard Medical School. To date, there are over 150 published clinical research papers about EIM, 10 issued patents and 2 that are pending, and over 10 pharmaceutical company-supported clinical studies. Myolex has worked collaboratively with clinical researchers and pharmaceutical scientists to enhance the data-gathering and data analytics capabilities for their neuromuscular trials. Myolex is now completing commercial development of a medical grade, skeletal muscle measurement device that is specifically designed to non-invasively, comprehensibly, and precisely detect, monitor, and display muscle abnormalities, to aid and support of clinicians who diagnose and treat neuromuscular disorders. The company’s first medical device commercial entry, the Myolex mScan®, is now following a clear pathway to FDA clearance.
